US biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the first to target CS1 protein – has started recruiting patients. The multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback